Table 2 Association of TET2 and 5hmC and clinicopathological characteristics of EC patients

Total

264

136 (51.52)

6 (0.76)

21 (7.95)

101 (38.26)

Age (year)

4.857

0.183

 ≥ 45

225

121 (53.78)

4 (1.78)

16 (7.11)

84 (37.33)

 < 45

39

15 (38.46)

2 (5.13)

5 (12.82)

17 (43.59)

Menopausal status

2.077

0.557

 Pre-menopause

93

52 (55.91)

3 (3.23)

6 (6.45)

32 (34.41)

 Post-menopause

171

84 (49.12)

3 (1.75)

15 (8.77)

69 (40.35)

Differentiation

82.249

< 0.001*

 Well

166

119 (71.69)

3 (3.61)

12 (7.23)

32 (19.28)

 Moderate

37

10 (27.03)

0 (0.00)

3 (8.11)

24 (64.86)

 Poor

61

7 (11.48)

3 (4.92)

6 (9.84)

45 (73.77)

Myometrial invasion

44.060

< 0.001*

 < 1/2

174

112 (64.38)

5 (2.87)

15 (8.62)

42 (24.14)

 ≥ 1/2

90

24 (26.67)

1 (1.11)

6 (6.67)

59 (65.56)

Lymph node metastasis

15.231

0.002*

 Negative

240

132 (55.00)

4 (1.67)

18 (7.50)

86 (35.83)

 Positive

24

4 (16.67)

2 (8.33)

3 (12.50)

15 (62.50)

FIGO Stage

38.769

< 0.001*

 I

195

121 (62.05)

3 (1.54)

15 (7.69)

56 (28.72)

 II

24

6 (25.00)

2 (8.33)

2 (8.33)

14 (58.33)

 III

45

9 (20.00)

1 (2.22)

4 (8.89)

31 (68.89)